Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study

Go back to Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 115.71 -1.22 (1.04%)
Previous Close $116.93    52 Week High $118.49 
Open $116.75    52 Week Low $55.00 
Day High $116.87    P/E N/A 
Day Low $115.12    EPS $-0.56 
Volume 1,476,823       

Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1273.46 -33.23 (2.54%)
Previous Close $1306.69    52 Week High $88.16 
Open $1304.15    52 Week Low $67.88 
Day High $1307.92    P/E 294.78 
Day Low $1257.62    EPS $4.32 
Volume 2,277,291